TAmiRNA´s osteomiR and thrombomiR sample testing service allows customers to ship their samples to the TAmiRNA service lab for analysis using its microRNA RUO test kits osteomiR and/or thrombomiR, taking advantage of TAmiRNA´s quality-controlled laboratory environment to achieve highest data quality and rapid turnaround times.
There is no minimum or maximum sample requirement: this service can be performed for any numbers of samples. Analysis requires only 225µL per serum or plasma sample.
The service includes:
- RNA isolation from biofluids (serum/plasma)
- Quality control of total RNA
- cDNA synthesis
- qPCR using either osteomiR or thrombomiRs plates
- Data normalization, analysis and result report
TAmiRNA offers optional enrichment for exosomes or microvesicles.
Quality control of all samples is included with excellent data quality ensured, because samples are handled by the very TAmiRNA scientists, who originally developed the kits.
The service offers two principal customer benefits:
- Test service performed by RNA experts in a quality-controlled environment
- Data analysis based on TAmiRNA´s data normalization pipeline, which ensures excellent data comparability, even across multiple centers
This allows academic and clinical research groups to obtain fast and uncomplicated insight into the nature of their samples, receiving high quality data, ready for presentation, publication and further analysis.
The osteomiR™ technology originated from an academic research project in the lab of Prof. Dr. Johannes Grillari at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, while thrombomiR™ was developed from an original academic research project in the lab of Dr. Manuel Mayr at the King´s British Heart Foundation Centre, King´s College London, UK.
Services performed with both tests require only 200 μL of fresh or frozen serum or plasma, which means they can be minimally invasive.
The kits are based on a simple technology platform and are particularly useful for clinical research groups and pharmaceutical companies that are active in bone quality and platelet function research.
The osteomiRTM kit provides a novel tool to analyze novel biomarker candidates for the prediction of fracture risk in postmenopausal women and can solve the problem of identifying patients in need of preventive therapy for bone fractures. The test is designed to provide a valuable complement to clinical parameters such as FRAXTM or bone mineral density, improving its test performances significantly.
The thrombomiR™ kit is based in the miRNA expression profiles within platelets which reflects platelet function that is independent of any specific activation pathway. Platelets play a key role in hemostasis, initiating and propagating thrombosis. Dysregulation and inappropriate activation of platelets occurs in a wide range of serious age-associated diseases, including stroke and myocardial infraction. Precise knowledge of the platelet status of a patient is also critical in clinical decision making, since impairment of platelet functions can result in bleeding disorders and additional risk during surgery.